Drugs / CAR-GPRC5D
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05759793 | Mar 2023 → Sep 2025 overdue | plasma cell leukemia | Nanjing IASO Biotechnology Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1 | NCT05219721 | Mar 2022 → Sep 2025 overdue | plasma cell leukemia, refractory plasma cell neoplasm | Chunrui Li | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2025-10-22 | Nanjing IASO Biotechnology Co., Ltd. | Results Blood Publishes Promising Results of IASO Bio's Anti-GPRC5D CAR-T RD118 in Relapsed/Refractory Multiple Myeloma iasobio.com ↗
The study demonstrates that RD118 exhibited significant efficacy and a manageable safety profile in heavily pretreated R/R MM patients, offering new therapeutic hope for the patients with a poor prognosis . |
| 2024-06-28 | Nanjing IASO Biotechnology Co., Ltd. | Regulatory Comprehensively Covering Multiple Myeloma: IASO Bio's GPRC5D CAR-T Product RD118 Receives IND Approval from NMPA iasobio.com ↗
today announces that the investigational new drug (IND) application for RD118, an independently developed, fully human GPRC5D-targeting chimeric antigen receptor T-cell (CAR-T) therapy, has been approved by the National Medical Products Administration (NMPA) for treatment of relapsed/refractory multiple myeloma (RRMM). |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-10-22 | Nanjing IASO Biotechnology Co., Ltd. | Blood Publishes Promising Results of IASO Bio's Anti-GPRC5D CAR-T RD118 in Relapsed/Refractory Multiple Myeloma iasobio.com ↗ |
| 2024-06-28 | Nanjing IASO Biotechnology Co., Ltd. | Comprehensively Covering Multiple Myeloma: IASO Bio's GPRC5D CAR-T Product RD118 Receives IND Approval from NMPA iasobio.com ↗ |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CAR-GPRC5D | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05219721 ↗ |
| Known as | RD118 | “CAR-GPRC5D (RD118) is an individualized, gene-modified autologous T-cell immunotherapy product targeting GPRC5D that identifies and eliminates malignant and normal cells...” NCT05759793 ↗ |
| Action | Deplete | “identifies and eliminates malignant and normal cells expressing GPRC5D” NCT05759793 ↗ |
| Modality | Cell therapy | “CAR-GPRC5D CAR-T cells” NCT05759793 ↗ |
| Target | GPRC5D | “targeting GPRC5D” NCT05759793 ↗ |